Legend Biotech Corporation is a biotechnology business based in the US. Legend Biotech Corporation shares (LEGN) are listed on the NASDAQ and all prices are listed in US Dollars. Legend Biotech Corporation employs 800 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Legend Biotech Corporation
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LEGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Legend Biotech Corporation stock price (NASDAQ: LEGN)Use our graph to track the performance of LEGN stocks over time.
Legend Biotech Corporation shares at a glance
|Latest market close||$39.37|
|52-week range||$23.41 - $49.49|
|50-day moving average||$40.67|
|200-day moving average||$31.89|
|Wall St. target price||$52.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.32|
Buy Legend Biotech Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Legend Biotech Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Legend Biotech Corporation price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-4.09%|
|3 months (2021-04-30)||30.80%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Legend Biotech Corporation financials
|Revenue TTM||$79.1 million|
|Gross profit TTM||$78.7 million|
|Return on assets TTM||-33.29%|
|Return on equity TTM||-1695.65%|
|Market capitalisation||$6.9 billion|
TTM: trailing 12 months
Shorting Legend Biotech Corporation shares
There are currently 1.9 million Legend Biotech Corporation shares held short by investors – that's known as Legend Biotech Corporation's "short interest". This figure is 7% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting Legend Biotech Corporation shares can be evaluated.
Legend Biotech Corporation's "short interest ratio" (SIR)
Legend Biotech Corporation's "short interest ratio" (SIR) is the quantity of Legend Biotech Corporation shares currently shorted divided by the average quantity of Legend Biotech Corporation shares traded daily (recently around 457518.1598063). Legend Biotech Corporation's SIR currently stands at 4.13. In other words for every 100,000 Legend Biotech Corporation shares traded daily on the market, roughly 4130 shares are currently held short.
However Legend Biotech Corporation's short interest can also be evaluated against the total number of Legend Biotech Corporation shares, or, against the total number of tradable Legend Biotech Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Legend Biotech Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Legend Biotech Corporation shares in existence, roughly 10 shares are currently held short) or 0.0614% of the tradable shares (for every 100,000 tradable Legend Biotech Corporation shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Legend Biotech Corporation.
Find out more about how you can short Legend Biotech Corporation stock.
Legend Biotech Corporation share dividends
We're not expecting Legend Biotech Corporation to pay a dividend over the next 12 months.
Legend Biotech Corporation overview
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Stocks similar to Legend Biotech Corporation
Legend Biotech Corporation in the news
Should Legend Biotech (NASDAQ:LEGN) Be Disappointed With Their 32% Profit?
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Frequently asked questionsWhat percentage of Legend Biotech Corporation is owned by institutions?
Currently 21.177% of Legend Biotech Corporation shares are held by institutions. How many people work for Legend Biotech Corporation?
Latest data suggests 800 work at Legend Biotech Corporation. When does the fiscal year end for Legend Biotech Corporation?
Legend Biotech Corporation's fiscal year ends in December. Where is Legend Biotech Corporation based?
Legend Biotech Corporation's address is: 2101 Cottontail Lane, Somerset, NJ, United States, 08873 What is Legend Biotech Corporation's ISIN number?
Legend Biotech Corporation's international securities identification number is: US52490G1022
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert